Australia markets closed

Imagion Biosystems Limited (IBX.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.0130-0.0010 (-7.14%)
At close: 02:54PM AEST

Imagion Biosystems Limited

5601 Oberlin Drive
Suite 100
San Diego, CA 92121
United States
855 564 5264

IndustryDiagnostics & Research
Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Geoff Hollis AGIA, BComm, CACFO & Company Sec.299.83kN/AN/A
Dr. Yalia Jayalakshmi Ph.D.Chief Devel. Officer479.51kN/AN/A
Dr. Isaac J. Bright M.D.MD & CEON/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Imagion Biosystems Limited provides medical imaging technologies using magnetic resonance. It has activities in nanotechnology; biotechnology; cancer diagnostics; and superparamagnetic relaxometry. The company develops MagSense, which is in Phase I clinical trials for the treatment of HER2 breast cancers; and PrecisionMRX, an iron oxide nanoparticle to detect cancer. Imagion Biosystems Limited has a collaborative research program with Patrys Limited to use the MagSense nanoparticles for enhancing brain tumor imaging and diagnosis. The company was incorporated in 2016 and is based in San Diego, California.

Corporate governance

Imagion Biosystems Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.